Skip to main content

Table 3 Patient characteristics according to treatment with the 11 most commonly used antidiabetic treatment strategies in 1842 patients with diabetes mellitus and CKD

From: Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease – cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort

 

Insulin

Dietary treatment

Metformin

Sulfonyl-ureas

Metformin + Insulin

Glinides

DPP-4 inhibitors

Metformin + Sulfonyl-ureas

Sulfonyl-ureas + Insulin

Metformin + DPP-4 inhibitors

DPP-4

inhibitors + Insulin

N

699

405

123

123

76

59

46

38

38

37

27

Percent

41.8

24.2

7.4

7.4

4.6

3.5

2.8

2.3

2.3

2.2

1.6

Age, years

64 ± 9

65 ± 8

64 ± 9

67 ± 6

64 ± 7

66 ± 6

65 ± 7

66 ± 5

66 ± 6

64 ± 8

65 ± 7

Male gender, n (%)

478 (68.4)

270 (66.7)

70 (56.9)

80 (65.0)

46 (60.5)

45 (76.3)

36 (78.3)

29 (76.3)

27 (71.1)

22 (59.5)

16 (59.3)

BMI, kg/m 2

32 ± 6

31 ± 6

33 ± 6

32 ± 5

35 ± 5

31 ± 5

34 ± 5

33 ± 6

34 ± 8

32 ± 5

36 ± 6

Hemoglobin, g/dL b

13.2 (12.2, 14.4)

13.6 (12.5, 14.8)

13.7 (12.2, 5.0)

13.4 (12.3, 14.5)

13.7 (12.4, 14.4)

13.5 (12.4, 14.5)

13.1 (12.1, 14.3)

13.1 (12.1, 14.4)

13.7 (12.7, 14.7)

14.1 (12.5, 15.1)

13.5 (12.8, 14.1)

HbA1c, % c

7.5 (6.8, 8.4)

6.7 (6.5, 7.1)

6.6 (6.3, 7.1)

6.8 (6.3, 7.5)

7.3 (6.8, 8.1)

6.7 (6.3, 7.0)

6.7 (6.3, 7.1)

7.3 (6.6, 7.9)

7.8 (7.0, 8.6)

6.7 (6.4, 7.2)

7.6 (6.6, 8.7)

eGFR, mL/min/1.73 m 2

43 ± 15

46 ± 17

56 ± 18

45 ± 12

55 ± 17

42 ± 10

45 ± 13

52 ± 16

42 ± 12

53 ± 17

41 ± 12

UACR, mg/gCrea

71 (11, 512)

34 (8, 253)

22 (7, 322)

45 (8, 319)

59 (7, 353)

51 (8, 245)

22 (5, 247)

56 (14, 408)

81 (12, 357)

29 (6, 441)

29 (14, 102)

Duration of CKD, n (%)

          

  ≥ 5 years

324 (46.4)

183 (45.3)

38 (30.9)

47 (38.2)

32 (42.1)

27 (45.8)

16 (34.8)

10 (26.3)

14 (36.8)

14 (37.8)

10 (37)

 3 – < 5 years

115 (16.5)

65 (16.1)

19 (15.5)

17 (13.8)

13 (17.1)

10 (17)

9 (19.6)

6 (15.8)

4 (10.5)

2 (5.4)

6 (22.2)

 1 – < 3 years

152 (21.8)

80 (19.8)

29 (23.6)

33 (26.8)

11 (14.5)

15 (25.4)

9 (19.6)

11 (29)

10 (26.3)

11 (29.7)

4 (14.8)

  < 1 year

84 (12)

63 (15.6)

27 (22)

25 (20.3)

11 (14.5)

6 (10.2)

11 (23.9)

7 (18.4)

5 (13.2)

8 (21.6)

6 (22.2)

CV disease, number (%) a

382 (54.7)

176 (43.5)

38 (30.9)

58 (47.2)

38 (50)

17 (28.8)

17 (37)

23 (60.5)

16 (42.1)

16 (43.2)

18 (66.7)

  1. Values are reported as numbers and percentages (based on all diabetic patients), mean values ± standard deviation, or medians (25th, 75th percentile), as appropriate
  2. Missings (n = 171) resulted mostly from combinations that were used less frequently
  3. a The composite of cardiovascular disease includes all patients with one or more of the following: cardiac valve replacement, aortic aneurysm, coronary artery disease, cerebrovascular disease, peripheral artery disease
  4. b For conversion of hemoglobin into SI units (mmol/L): multiply with 0.62
  5. c For conversion of HbA1C into IFCC units (mmol/mol): (10.93 × HbA1C in %)-23.5